A multicentre, randomized, double-blind, placebo-controlled parallel design trial of the efficacy and safety of subcutaneous tetrodotoxin (TTX) for moderate to severe inadequately controlled cancer-related pain.

The study aimed to determine the safety and effectiveness of TTX in relieving pain and improving quality of life. In addition, the time to the start of the pain relief and its duration was studied and also whether TTX helped in reducing the use of other painkiller medications. Physical and emotional functioning of patients will also be measured.